Zoetis Inc. $ZTS Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 3.1% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 363,541 shares of the company’s stock after selling 11,643 shares during the quarter. New York State Teachers Retirement System’s holdings in Zoetis were worth $45,741,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in ZTS. Brighton Jones LLC boosted its stake in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after buying an additional 2,978 shares during the last quarter. Empowered Funds LLC increased its stake in shares of Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after acquiring an additional 657 shares during the last quarter. Intech Investment Management LLC increased its stake in shares of Zoetis by 17.2% in the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after acquiring an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in shares of Zoetis by 73.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after acquiring an additional 1,422 shares during the period. Finally, Glenview Trust co boosted its position in shares of Zoetis by 11.8% during the 2nd quarter. Glenview Trust co now owns 4,780 shares of the company’s stock valued at $745,000 after acquiring an additional 506 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Trading Down 0.7%

NYSE ZTS opened at $114.22 on Friday. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The firm has a market cap of $48.05 billion, a price-to-earnings ratio of 18.97, a PEG ratio of 1.77 and a beta of 0.87. The firm has a 50 day simple moving average of $119.93 and a 200-day simple moving average of $124.79. Zoetis Inc. has a one year low of $112.97 and a one year high of $172.23.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same period in the prior year, the business earned $1.40 EPS. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts anticipate that Zoetis Inc. will post 7.02 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.9%. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ZTS. William Blair reissued an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. UBS Group dropped their price target on shares of Zoetis from $136.00 to $130.00 and set a “neutral” rating for the company in a research note on Tuesday. Citigroup assumed coverage on shares of Zoetis in a report on Wednesday, April 15th. They set a “buy” rating and a $145.00 price target for the company. Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Finally, Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $151.75.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.